ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
23 announcements with these filters
Revenue rose 27.9% to ₹85.4 Cr, but EBITDA and PAT margins both contracted, and capex of ₹19.9 Cr far exceeds ₹7.2 Cr operating cash flow.
H1 FY27 revenue ₹85.4cr (+27.9%), EBITDA ₹18.3cr (+25.1%, 21.5% margin), PAT ₹12.0cr (+20.0%). Capacity expansion and wellness launches drive growth.
Influx Healthtech Ltd reported revenue from operations of ₹85.4 Cr (+27.8% YoY) and net profit of ₹12 Cr (+20.0% YoY) for H1 FY27.
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
Influx Healthtech Limited held its 6th Annual General Meeting on September 18, 2026. The company transacted the business items as per the AGM notice.
Influx Healthtech dispatched letters to shareholders without registered emails with the FY 2025-26 Annual Report weblink and 6th AGM notice. The letters are sent under Regulation 36(1)(b) of the SEBI Listing Regulations.
Influx Healthtech Ltd. has announced its 6th Annual General Meeting scheduled for September 18, 2026, and submitted its Annual Report for FY 2025-2026.
The Board approved the Directors' Report for FY26 and fixed the 6th AGM for September 18, 2026. They also appointed a scrutinizer for the upcoming meeting.
Influx Healthtech reallocated ₹10 Crore to expand its CDMO facility to 75,000 sq. ft. The expansion targets a 2.5x capacity increase by August 2026.
Influx Healthtech reported FY26 revenue of ₹146cr, a 41% YoY increase, with PAT at ₹20.5cr. Strategy focuses on scaling nutraceutical CDMO capacity by 2.5x through a new 75,000 sq ft facility.
Influx Healthtech delivered strong 41% YoY revenue growth in H2 FY26, driven by nutraceuticals, despite margin pressure from aggressive hiring ahead of massive capacity expansion.
Influx Healthtech delivered strong FY26 performance as a specialist CDMO in nutraceuticals and cosmetics, focusing on capacity expansion and new technology implementation following its 2025 NSE listing.
Influx Healthtech reported FY26 revenues of ₹146.83 Crore, up 40% year-on-year. Strong growth in nutraceuticals and ayurvedic segments drove record profitability and operational expansion.
Influx Healthtech Limited appointed M/s. Phirodia bafna & Associates as Internal Auditors for twelve months. The firm brings over 43 years of professional audit legacy.
Influx Healthtech Ltd reported revenue from operations of ₹80.1 Cr (+41.0% YoY) and net profit of ₹10.5 Cr (+36.4% YoY) for H2 FY26.
Influx Healthtech reported its audited financial results for the year ended March 31, 2026. The board also appointed M/s. Phirodia bafna & Associates as internal auditors.
Influx Healthtech scheduled a board meeting on May 20, 2026, to approve annual audited financial results. This meeting will determine the company's fiscal year performance.
Influx Healthtech Limited announced the successful passage of two special resolutions via postal ballot with requisite majorities. The resolutions concerned the alteration of IPO objects and the appointment/sitting fee approval for Mr. Mohmad Saleh Mutvalli as an Independent Director. Both resolutions received 100% of the valid votes cast in favour.
Influx Healthtech Limited informed the exchange that it does not qualify as a 'Large Corporate' as of March 31, 2026. The company reported zero outstanding long-term borrowings and stated that credit rating criteria were not applicable, ensuring compliance with SEBI debt-raising norms.
Influx Healthtech Limited issued a Q4FY26 business update highlighting robust operational growth and ₹5 Crore in internal accrual-funded capex. Key developments include commissioning several advanced production machines, incorporating a new subsidiary (OLAHEY WELLNESS PVT LTD), and clearing a regulatory audit in Tanzania. The company is transitioning towards a high-margin, innovation-led CDMO model.
Influx Healthtech Limited has submitted its Structural Digital Database (SDD) Compliance Certificate for the financial year ended March 31, 2026. The certificate, issued by Deepti & Associates, confirms the company maintained a non-tamperable database with audit trails for 41 required events in compliance with SEBI Insider Trading regulations.
Influx Healthtech Limited announced a reallocation of ₹10.09 Crore from its IPO proceeds. The funds, originally for veterinary and machinery divisions, will now support the expansion of its Nutraceutical CDMO facility from 35,000 to 75,000 sq. ft. The company set a voluntary 90% shareholder approval threshold for the variation, which is expected to be completed within 180 days.
Influx Healthtech Limited issued a corrigendum to its April 1, 2026, Postal Ballot Notice. The amendment updates the appointment of Mr. Nayan P. Pitroda as the Scrutinizer, replacing M/s. Richi Prerak & Associates. The e-voting period remains active from April 2 to May 1, 2026.